

## Director appointment

### Reece O'Connell appointed Non-Executive Director

**11 December 2024** - [Identitii \(ASX:ID8\)](#) ('Identitii', 'the Company') (ASX:ID8) is pleased to announce the appointment of Reece O'Connell as Non-Executive Director of the Company, effective today.

Reece O'Connell is an experienced fund manager who brings capital markets and investor relations skills, experience and network connections to the Identitii Board. He specialises in recognising and funding early-stage technology companies, including Arovella Therapeutics Ltd (ASX:ALA), Dimerix Ltd (ASX:DXB), Neurizon Therapeutics Ltd (ASX:NUZ, formerly PharmAust Ltd ASX:PAA), Orthocell Ltd (ASX:OCC), Race Oncology Ltd (ASX:RAC) and Respiro Ltd (ASXRSH).

Reece is currently Fund Manager of Summit Biotech Fund (formerly Merchant Biotech Fund), delivering client value through specialised knowledge and strategic investment in technology companies that are pioneering world-changing innovations. Reece holds an MBA (Innovation and Leadership), Bachelor of Business (Finance), Graduate Diploma of Financial Planning, and is certified in Securities and Derivatives Tier 1 (DFS3) and Managed Investments Tier 1 (DFS4).

**Commenting on his appointment, Reece O'Connell said:** "I have always taken a great interest in the management teams of the companies I invest in. The vision and passion driving the company, their previous track records of success, and their "skin in the game" are all critical success factors. I see all these success factors in Identitii, together with not one, but several promising opportunities the Company is pursuing to create significant shareholder value. I'm excited to join the Board of Directors and believe my skills, experience and network can help the Company deliver value for shareholders."



Commenting on the announcement, Tim Phillipps, Chair of Identitii, said: “There are several exciting opportunities in front of Identitii presently, particularly in light of recent reforms to the Anti-Money Laundering and Counter-Terrorism Financing Act 2006 (the AML/CTF Act) passed by Parliament, and the Board is committed to ensuring the Company is appropriately funded to capitalise on them. We’ve got to know Reece through the recruitment process and his appointment as Non-Executive Director adds significant capability to the Board. We are looking forward to working with him.”

Ends

This announcement has been approved and authorised to be given to ASX by the Board of Identitii Limited.

## About Identitii

Identitii’s mission is to seamlessly connect the world’s payment data. Current data sharing methods are manual and unstructured, exposing organisations to inefficiencies and elevated risk. Our platform is being used by more than 200 teams across the world, to structure and automate information sharing, improving the security and control of sensitive data as it moves within and between payments organisations. We fundamentally believe that the future of digital commerce will be enabled by greater access to, and sharing of, payments data within and across the boundaries of geography, residency and technology.

For more information visit: [www.identitii.com](http://www.identitii.com)

Visit Identitii’s interactive Investor Hub: If you have any questions about this announcement or any past Identitii announcements, or would like to see video summaries on important announcements, please visit our investor hub at: <https://investorhub.identitii.com/>

For more information, please contact:

Identitii

Michael Kotowicz

E: [investors@identitii.com](mailto:investors@identitii.com)

P: +61 416 233 145

